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https://doi.org/10.1016/j.celrep.2020.107940SUMMARYSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral dis-
ease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum
antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir
(RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cul-
tures (EC50 = 0.01 mM). Weaker activity is observed in Vero E6 cells (EC50 = 1.65 mM) because of their low ca-
pacity to metabolize RDV. To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding
the viral target of RDV, the RNA-dependent RNA polymerase of SARS-CoV-2. In mice infected with the
chimeric virus, therapeutic RDV administration diminishes lung viral load and improves pulmonary function
compared with vehicle-treated animals. These data demonstrate that RDV is potently active against SARS-
CoV-2 in vitro and in vivo, supporting its further clinical testing for treatment of COVID-19.INTRODUCTION
Coronaviruses (CoVs) are genetically diverse positive-sense
RNA viruses that circulate in animals and humans. In the past
20 years, three new human CoVs have emerged: severe acute
respiratory syndrome CoV (SARS-CoV) in 2002, Middle East res-
piratory syndrome (MERS)-CoV in 2012, and SARS-CoV-2, the
causative agent of the current CoV disease 2019 (COVID-19)
pandemic (de Wit et al., 2016; Zhou et al., 2020b). Although
four endemic human CoVs (HCoV-OC43, -229E, -NL63, and
-HKU1) typically cause mild respiratory disease with common
cold-like symptoms, SARS-CoV, MERS-CoV, and SARS-CoV-
2 cause severe respiratory disease with respective mortality
rates of 11% (Chan-Yeung and Xu, 2003), 35% (Arabi et al.,
2017), and an estimated 3% (Chen, 2020). The development of
effective broad-spectrum antiviral agents has been hampered
by viral diversity, the capacity of CoVs to adaptively overcome
negative selective pressure, and the ability to actively counteract
drugs through the action of a proofreading exoribonuclease. We
reported previously that remdesivir (RDV), a monophosphorami-
date prodrug of theC-adenosine analog GS-441524, potently in-This is an open access article under the CC BY-Nhibits replication of a broad spectrum of pre-pandemic bat CoVs
and human epidemic CoVs in primary human lung cell cultures
(Agostini et al., 2018; Brown et al., 2019; Sheahan et al., 2017).
Biochemical analysis of the mechanism of inhibition of the
SARS-CoV-2, SARS-CoV, and MERS-CoV RNA-dependent
RNA polymerase (RdRp) revealed that incorporation of the active
metabolite RDV triphosphate (RDV-TP) was more efficient than
the natural substrate ATP and led to delayed chain termination
3 nt downstream of incorporation (Gordon et al., 2020a,
2020b). Prolonged passaging of murine hepatitis virus (MHV), a
group 2a CoV, in the presence of GS-441524 resulted in low-
level resistance through mutations in the RdRp, further impli-
cating this protein as the drug target (Agostini et al., 2018).
RDV showed prophylactic and therapeutic efficacy in mouse
models of SARS and MERS and against MERS-CoV challenge
in a rhesus macaque model (Sheahan et al., 2017, 2020a; de
Wit et al., 2020). Here we report that RDV potently inhibits
SARS-CoV-2 replication in Calu3 human lung cells with sub-
micromolar 50% maximal effective concentration (EC50) and in
primary human airway epithelial (HAE) cultures with nanomolar
EC50. Notably, we detected a comparably lower potency ofCell Reports 32, 107940, July 21, 2020 ª 2020 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Modeling of RDV onto the SARS-
CoV-2 RdRp Structure
(A) Model of the SARS-CoV-2 polymerization
complex in its elongating state. The model was
based on the cryo-EM apo structures of SARS-
CoV (http://www.rcsb.org/structure/6NUR) and
SARS-CoV-2 (http://www.rcsb.org/structure/
6M71). The active site is boxed in red.
(B) Enlarged view of the active site, depicting RDV
pre-incorporation. The 10CN substituent sits in a
shallow pocket formed by residues T687 and
A688. Bound to the two catalytic Mg2+ ions (pink),
the TP is coordinated by two basic residues (R553
and R555).
See also Figures S1–S3.
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lower metabolic capacity to activate the compound. Mice in-
fected with chimeric SARS-CoV encoding the SARS-CoV-2
RdRp and treated therapeutically with RDV show decreased viral
loads in the lungs and increased pulmonary function. These data
emphasize the potential of RDV as a promising countermeasure
against the ongoing COVID-19 pandemic.
RESULTS
A Structural Model of RDV Incorporation by the SARS-
CoV-2 Polymerase and Conservation of the Active Site
across Human CoV
Drug function and performance are heavily influenced by micro-
variation in target genes across virus families, biodistribution in
the organism, and, importantly, host cell and tissue expression
patterns that influence drug stability and metabolism. We previ-
ously modeled RDV on a homology model of SARS-CoV-2
based on the cryo-EM structure of the SARS-CoV polymerase
complex (Gordon et al., 2020b; Kirchdoerfer and Ward, 2019).
Composed of nsp12, nsp7, and nsp8, the model was consistent
with biochemical findings predicting efficient incorporation of
RDV-TP into the growing RNA strand and provided an explana-
tion for the observed delayed chain termination after incorpora-
tion of three additional nucleotides. We have since refined this
model using the recently released cryoelectron microscopy
(cryo-EM) structure of the SARS-CoV-2 polymerase complex
(Gao et al., 2020). The major qualitative change is a more com-
plete picture of the N-terminal NiRAN (nidovirus RdRp-associ-
ated nucleotidyltransferase) domain of nsp12, which was not
resolved in the SARS-CoV structure. The current model of the
pre-incorporation state, with RDV-TP, RNA primer and template
strands, and catalytic metals was well-optimized with a series of
constrained energy minimizations and conformational searches,
as described previously (Figure 1A). Bound to the two catalytic
Mg2+ ions, RDV-TP is coordinated by two basic residues (R553
and R555). The ribose 20OH forms hydrogen bonds to T680
and N691, and the 10CN resides in a shallow pocket formed by
T687 and A688 (Figure 1B). The interaction with T680 distin-
guishes CoVs from other structurally related families, including
noroviruses, picornaviruses, and flaviviruses. Although key resi-2 Cell Reports 32, 107940, July 21, 2020dues, including D623, S682, and N691, are conserved across all
of these virus families and have been shown to govern posi-
tioning of the nucleoside triphosphate (NTP) into the active
site, the role of T680 appears to be novel. While writing this
manuscript, another model of RDV-TP in the SARS-CoV-2 active
site (Shannon et al., 2020) was published that predicts a role for
S682 as well. The position of T680 relative to N691 strongly im-
plies that it will contribute to recognition of the ribose 20OH, likely
diminishing the role of S682 as a result, consistent with earlier
predictions (Kirchdoerfer and Ward, 2019). Furthermore, while
this manuscript was under review, a cryo-EM ternary structure
of the complex with RDV was released (Yin et al., 2020). The
new structure (PDB: 7BV2) aligned with the model with a root-
mean-square deviation (RMSD) of 0.91 Å, with an RMSD of
1.66 Å for the double-stranded RNA (dsRNA) less the template
overhang. Even though the new structure captures the post-
incorporation/pre-translocation state, and our model depicts
the pre-incorporation state, the new structure predicts no inter-
action between S682 and the incorporated RDV and, thus, con-
firms its diminished role. This contrasts with structures that cap-
ture this same post-incorporation state of the poliovirus
polymerase, in which the homologous serine residue is seen to
directly hydrogen-bond to the 20OH of the incorporated nucleo-
tide (Gong and Peersen, 2010). The new structure also reinforces
our previous prediction (Gordon et al., 2020b) that S861 is the
residue most likely responsible for the delayed chain termination
caused by RDV incorporation.
Modeling of the RDV resistance mutations identified in MHV
(Agostini et al., 2018) onto the homologous residues V557 and
F480 in the SARS-CoV-2 RdRp structure reveals that V557L
shifts the position of the template base, which, in turn, shifts
the positioning of the incoming NTP (Figures S1A and S1B).
This will affect RDV activity in that it alters the position of the
10CN in the pocket. Because the model predicts no direct inter-
action of F480 with the NTP, primer, or template, the effect of the
F480L mutation is more difficult to discern. The F480L mutation
could potentially induce a subtle change to the 10CN binding
pocket (Figures S1C and S1D). Alignment of nsp12 sequences
from SARS-CoV-2 used in other studies of RDV shows complete
conservation of nsp12 nucleotide sequences, predicting compa-
rable antiviral activity of RDV against these isolates (Figure S2).
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SARS-CoV (Figure S3A), MERS-CoV (Figure S3B), HCoV-OC43
(FigureS3C), HCoV-229E (Figure S3D), HCoV-NL63 (FigureS3E),
and HCoV-HKU1 (Figure S3F). The models show that SARS-
CoV-2 is identical to SARS-CoV out to a radius of 18 Å from
the active site. Differences detected on the periphery of the
active site of MERS-CoV and HCoV-OC43, -229E, -NL63, and
-HKU1 correspond to residues that do not directly interact with
RDV-TP. Together, these data demonstrate high structural con-
servation of the RdRp active site interacting with RDV-TP across
all seven known human CoV strains.
RDV and GS-441524 Potently Inhibit SARS-CoV-2
Replication
RDV and its parent nucleoside analog GS-441524 inhibit CoVs
and multiple other viruses (Agostini et al., 2018; Cho et al.,
2012; Lo et al., 2017; Sheahan et al., 2017; Warren et al.,
2016). Previous reports (Choy et al., 2020; Wang et al., 2020;
Runfeng et al., 2020) suggest that RDV inhibits SARS-CoV-2,
but comparative studies of anti-SARS-CoV-2 activity using
authentic compounds in physiologically relevant cell lines are
lacking. We first compared SARS-CoV-2 replication in estab-
lished cell lines to determine which cell types could potentially
be suitable for studying RDV efficacy against SARS-CoV-2. Viral
yields were determined 24, 48, and 72 h post-infection (hpi) in
Vero E6, Vero CCL-81 (Vero), Huh7, and Calu3 2B4 cells (Yoshi-
kawa et al., 2010; Figure 2A). Vero E6 and Vero cells supported
the highest levels of SARS-CoV-2 replication, consistent with a
previous study (Harcourt et al., 2020). Maximum yields were de-
tected at 48 hpi in Vero E6 cells (>6 logs at MOI = 0.1 and 0.01
PFU/cell), 24 hpi in Vero cells infected at MOI = 0.1 PFU (>5
logs), 48 hpi in Vero cells infected at MOI = 0.01 PFU/cell (>5
logs), 72 hpi in Calu3 2B4 cells (>4 logs at MOI = 0.1 PFU/cell),
and 48 hpi in Huh7 cells (>4 logs at MOI = 0.1 PFU/cell and <2
logs at MOI = 0.01 PFU/cell). These results indicate that Vero
E6, Vero, and Calu3 2B4 cells support varying levels of SARS-
CoV-2 replication and that the cell type should be chosen for a
given study depending on the study goals.
To determine whether RDV and GS-441524 inhibit SARS-
CoV-2 replication in established cell lines, Calu3 2B4 human
lung adenocarcinoma cells and Vero E6 African green monkey
kidney cells were infected with the SARS-CoV-2 clinical isolate
2019-nCoV/USA-WA1/2020 and treated with a range of RDV
or GS-441524 concentrations. Supernatants were harvested at
time points corresponding to peak viral replication for each cell
type, and infectious viral titers and viral genome copy numbers
in the supernatant were quantified by plaque assay and qRT-
PCR, respectively. RDV and GS-441524 potently inhibited
SARS-CoV-2 replication in a dose-dependent manner in both
cell types (Figure 2; Table 1). In Calu3 2B4 cells, both com-
pounds displayed dose-dependent inhibition of viral replication,
as determined by plaque assay (Figure 2B) and qRT-PCR (Fig-
ure 2C). RDV inhibited SARS-CoV-2 with an EC50 value of
0.28 mMand a 90%maximal effective concentration (EC90) value
of 2.48 mM. The parent compound GS-441524 displayed similar
potency: an EC50 value of 0.62 mM and EC90 value of 1.34 mM
(Figure 2D; Table 1). EC50 values determined by quantification
of viral genome copies showed a similar trend (Figure 2E; Table1). Both compounds also displayed dose-dependent inhibition
of viral replication in Vero E6 cells, as determined by infectious
viral titers and genome copy numbers (Figure 2F). RDV inhibited
SARS-CoV-2 with an EC50 value of 1.65 mM and EC90 value of
2.40 mM. However, in this cell type, GS-441524 was more potent
(EC50 = 0.47 mM and EC90 = 0.71 mM) than RDV, as determined
by infectious viral titers (Figure 2G; Table 1) and genome copy
numbers (Figure 2H; Table 1). Thus, RDV inhibits SARS-CoV-2
more potently in Calu3 2B4 than in Vero E6 cells, and the relative
potencies of the prodrug and parent nucleoside are cell type
dependent.
RDV Is a Highly Potent Antiviral Inhibitor of SARS-CoV-2
in Primary HAE Cultures
SARS-CoV-2 is known to replicate in the upper and lower
airways in humans (Adachi et al., 2020; Wölfel et al., 2020). In
addition, we have shown recently that SARS-CoV-2 replicates
in human primary cells from the nasal to alveolar epithelium
(Hou et al., 2020). To demonstrate the antiviral activity of RDV
against SARS-CoV-2 in a human primary epithelial culture sys-
tem, we performed antiviral assays in HAE cultures, which are
grown on air-liquid interface and recapitulate the cellular
complexity and physiology of the human conducting airway
(Sims et al., 2005). HAE cultures are the model system in which
we have amassed data for many other enzootic, emerging, and
endemic CoVs, allowing comparison of SARS-CoV-2 data with
previous reports (Sheahan et al., 2017, 2020a). In RDV-treated,
SARS-CoV-2-infected HAE cultures, we observed a dose-
dependent reduction in infectious virus production with more
than 100-fold inhibition at the highest tested concentration (Fig-
ure 3A). Importantly, RDV demonstrates potent antiviral activity
with EC50 values of 0.0010 and 0.009 mM in two independent ex-
periments (Figure 3B). Similar to previously reported studies,
RDV did not cause cytotoxicity in HAE cultures across the
dose range where we see potent antiviral effects (Figure S4;
Sheahan et al., 2017). Together, these data demonstrate that
RDV is potently antiviral against SARS-CoV-2 in primary human
lung cultures with a selectivity index of more than 1,000.
Antiviral Activities of RDVandGS-441524Correlatewith
RDV-TP Metabolite Levels
Cell-type-specific expression of genes for enzymes that metab-
olize ribonucleoside analogs and their prodrugs can have a
profound effect on activity (Eriksson, 2013; Koczor et al.,
2012). Table 1 and prior studies (Bojkova et al., 2020; Choy
et al., 2020; Jeon et al., 2020) demonstrate that the antiviral ac-
tivity of RDV against SARS-CoV-2 is highly variable in different
cell culture models. RDV and GS-441524 undergo intracellular
conversion to the active metabolite RDV-TP, involving several
metabolic steps (Figure S5), and the efficiency of each step
might differ between cell types. Therefore, to reconcile the differ-
ences in antiviral activity of RDV and GS-441524 observed in our
and other studies, we compared intracellular RDV-TP concen-
trations in Vero E6, Calu3 2B4, and HAE cultures following com-
pound incubation. RDV-TP levels per million cells produced after
8- to 48-h treatment with RDV were substantially higher in pri-
mary HAE cultures than in Calu3 2B4 or Vero E6 cultures (Fig-





A Figure 2. The ProdrugRemdesivir (RDV) and
Parent Nucleoside GS-441524 (’524)
Potently Inhibit SARS-CoV-2 Replication
(A) Vero E6, Vero CCL-81 (Vero), Huh7, and Calu3
2B4 cells were infected with an MOI of 0.01 and/or
0.1 PFU/cell SARS-CoV-2 (2019-nCoV/USA-WA1/
2020), and infectious viral titers were determined
by plaque assay 0.5, 24, 48, and 72 h post-infec-
tion (hpi). Viral yields were calculated by sub-
tracting the average 0.5 h (post-adsorption, pre-
incubation) titer from each subsequent time point.
Data represent the average of three replicates from
one experiment. Error bars indicate SD. B.D.,
below detection. Calu3 2B4 cells were infected
with 0.1 PFU/cell SARS-CoV-2, and Vero cells
were infected with 0.01 PFU/cell SARS-CoV-2 and
treatedwith RDV, GS-441524 (’524), or DMSOonly
(control) in cell culture medium. Supernatants were
collected 48 hpi (Vero E6 cells) or 72 hpi (Calu3 2B4
cells).
(B and C) Reduction of SARS-CoV-2 replication by
RDV in Calu3 2B4 cells, as determined by infec-
tious viral titer (B) and qRT-PCR (C).
(D) Percent inhibition of SARS-CoV-2 replication
by RDV and GS-441524 in Calu3 2B4 cells, as
determined by infectious viral titer (RDV: EC50 =
0.28 mM, EC90 = 2.48 mM; GS-441524: EC50 =
0.62 mM, EC90 = 1.34 mM). No significant cytotox-
icity of either compound was detected in Calu3
cells.
(E) Percent inhibition of SARS-CoV-2 replication by
RDV and GS-441524 in Calu3 2B4 cells, as
determined by qRT-qPCR (RDV: EC50 = 0.60 mM,
EC90 = 1.28 mM; GS-441524: EC50 = 1.09 mM,
EC90 = 1.37 mM).
(F and G) Reduction of SARS-CoV-2 replication by
RDV in Vero E6 cells, as determined by infectious
viral titer (F) and qRT-PCR (G).
(H) Percent inhibition of SARS-CoV-2 replication
by RDV and GS-441524 in Vero E6 cells, as
determined by infectious viral titer (RDV: EC50 =
1.65 mM, EC90 = 2.40 mM; GS-441524: EC50 =
0.47 mM, EC90 = 0.71 mM). No significant cytotox-
icity of either compound was detected in Vero E6
cells.
(I) Percent inhibition of SARS-CoV-2 replication by
RDV and GS-441524 in Vero E6 cells, as deter-
mined by qRT-PCR (RDV: EC50 = 1.49 mM, EC90 =
3.03 mM; GS-441524: EC50 = 0.47 mM, EC90 =
0.80 mM).
Data represent means of 2–4 independent exper-
iments with 2–3 replicates each. Error bars repre-
sent SEM. See also Figure S5.
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See also Table S1 and Figure S5.
aGS-441524 was not tested for antiviral potency or RDV-TP levels in HAE
cultures.
bHAE antiviral potencies and RDV-TP levels were determined indepen-
dently in differentiated cultures from two donors. RDV-TP levels in HAE
cultures are presented as the mean ± SD of quadruplicate technical rep-
licates from two donors.
cIndividual analyte data are presented in Tables S1 and S2.
dValues represent mean ± SD from four independent experiments, each
performed with duplicate samples.
eValues represent mean ± SD from two independent experiments, each
performed with duplicate samples.
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similar demographic profiles. RDV-TP was formed efficiently in
both donor cultures following incubation with RDV, with a differ-
ence of less than 3-fold from each other. The lowest levels of
RDV-TP were observed following RDV treatment of Vero E6 cells
and were approximately 4- and 20-fold lower than those
observed in Calu3 2B4 and HAE cultures, respectively. Incuba-
tion of Vero E6 cells with GS-441524 yielded 3.5-fold higher
RDV-TP levels compared with incubation with RDV, correspond-
ing to higher antiviral potency of GS-441524 relative to RDV
(Table S1). In conclusion, the RDV-TP levels in the different cell
types directly correlated with the antiviral potency of RDV
against SARS-CoV-2. HAE cultures produced substantially
higher levels of RDV-TP, which translated into markedly more
potent antiviral activity of RDV (Table 1). Importantly, the meta-
bolism of RDV in Vero E6 cells appeared to be less efficient,
particularly in comparison with the HAE cultures, indicating
that Vero E6 cells might not be an appropriate cell type to char-
acterize the antiviral activity of RDV and, potentially, also other
nucleotide prodrug-based antiviral agents.
RDV Is Active against the SARS-CoV-2 RdRp In Vivo
SARS-CoV-2 does not bind themurine ortholog of the human en-
try receptor (i.e., mouse angiotensin-converting enzyme-2
[mACE2]) to enter cells (Zhou et al., 2020b). To rapidly assess
the therapeutic efficacy of RDV against SARS-CoV-2 in vivo,
we constructed a chimeric mouse-adapted SARS-CoV variant
encoding the target of RDV antiviral activity, the RdRp, of
SARS-CoV-2 (SARS/SARS2-RdRp) (Figure 5A). Although other
chimeric replicase open reading frame (ORF) recombinant
CoVs have been shown to be viable (Stobart et al., 2013), this
is the first demonstration that the RdRp from a related but
different CoV can support efficient replication of another. After
recovery and sequence confirmation (Figure 5B) of recombinantchimeric viruses with and without a nanoluciferase reporter, we
compared SARS-CoV and SARS/SARS2-RdRp replication and
sensitivity to RDV in Huh7 cells. Replication of both viruses
was inhibited similarly in a dose-dependent manner by RDV
(SARS-CoV mean EC50 = 0.007 mM, SARS/SARS2-RdRp mean
EC50 = 0.003 mM) (Figures 5C and 5D). We then determined
the therapeutic efficacy of RDV against the SARS/SARS2-
RdRp in mouse models employed for previous studies of RDV
(Sheahan et al., 2017). Mice produce a serum esterase absent
in humans, carboxyl esterase 1c (Ces1c), which dramatically re-
duces the half-life of RDV. Thus, to mirror pharmacokinetics
observed in humans, mouse studies with RDV must be per-
formed in transgenic C57BL/6 Ces1c/ mice (Sheahan et al.,
2017). We infected female C57BL/6 Ces1c/ mice with 103
PFU SARS/SARS2-RdRp and initiated subcutaneous treatment
with 25 mg/kg RDV BID 1 day post-infection (dpi). This regimen
was continued until study termination. Although weight loss and
lung hemorrhage did not differ significantly between vehicle-
and RDV-treated animals (Figures 5E and 5F), we found differ-
ences in pulmonary function, as measured by whole-body
plethysmography (WBP) between RDV- and vehicle-treated an-
imals. The WBP metric, PenH, is a surrogate marker of pulmo-
nary obstruction (Menachery et al., 2015a). Therapeutic RDV
significantly ameliorated the loss of pulmonary function
observed in the vehicle-treated group (Figure 5G). Importantly,
RDV treatment dramatically reduced the lung viral load (Fig-
ure 5H). Taken together, these data demonstrate that therapeu-
tically administered RDV can reduce virus replication and
improve pulmonary function in an ongoing infection with a
chimeric SARS-CoV/SARS-CoV-2 virus encoding the RdRp
target of RDV.
DISCUSSION
The COVID-19 pandemic has gravely illustrated the need for
countermeasures against emerging epidemic and pandemic
CoVs. Broad-spectrum antiviral drugs, antibodies, and vaccines
are needed to combat the current pandemic and those that will
emerge in the future. RDV shows potent activity against an array
of genetically diverse CoVs as well as against unrelated
emerging viruses like Ebola (Agostini et al., 2018; Brown et al.,
2019; Sheahan et al., 2017, 2020a; Warren et al., 2016). In this
study, we demonstrate that RDV and its parent nucleoside GS-
441524 are active against SARS-CoV-2 in the physiologically
relevant Calu3 2B4 cell line and that RDV has strong antiviral ac-
tivity in primary human airway cultures. The potency of RDV was
directly related to the intracellular concentration of the pharma-
cologically active TP metabolite, which was markedly higher in
primary HAE cultures compared with human lung cells (Calu3
2B4) and monkey kidney cells (Vero E6). Our data are consistent
with recent studies demonstrating important contributions of
natural variation in host- and tissue-specific gene expression
patterns and microbiome-specific contributions to drug meta-
bolism, stability, and bioavailability in different tissues (Eriksson,
2013; Koczor et al., 2012). Modeling of RDV-TP onto the SARS-
CoV-2 RdRp revealed that the positioning of RDV-TP into the
active site closely resembled that of the cognate natural sub-
strate ATP, consistent with efficient incorporation into RNACell Reports 32, 107940, July 21, 2020 5
A B Figure 3. RDV Is Potently Antiviral against
SARS-CoV-2 in Primary Human Airway
Epithelial (HAE) Cultures
HAE cultures were infected with a SARS-CoV-2
clinical isolate (2019-nCoV/USA-WA1/2020) at an
MOI of 0.5 PFU/cell for 2 h, and then the virus was
removed and cultures were washed 3 times, fol-
lowed by incubation at 37C for 48 h.
(A) SARS-CoV-2 infectious virus production in two
independent studies. The virus was titered via pla-
que assay in apical washes 48 hpi. Each symbol
represents the titer from a single culture, and a line is
drawn at the mean.
(B) Percent inhibition generated from the titer data in
(A).
See also Figure S4.
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OPEN ACCESSduring replication of the viral genome. RDV decreased viral loads
and improved lung function in mice infected with the SARS/
SARS2-RdRp chimeric virus when treated at 1 dpi. This is the
first rigorous demonstration of potent inhibition of SARS-CoV-2
in continuous and primary human lung cultures and the
first study suggesting efficacy of RDV against SARS-CoV-2 in
mice.
Previous studies of RDV anti-SARS-CoV-2 activity reported
EC50 values of 0.77 mM as determined by quantification of
genome copy number (Wang et al., 2020), 23.2 mM as deter-
mined by 50% tissue infectious dose (TCID50), 26.9 mMas deter-
mined by RNA copy number (Choy et al., 2020), and 0.65 mM as
determined by cytopathic effect (CPE) (Runfeng et al., 2020), all
in Vero E6 cells. The potency of RDV in Vero E6 cells (EC50,
1.65 mM) observed in our study is comparable with values re-
ported byWang et al. (2020) and Runfeng et al. (2020) but greater
than reported by Choy et al. (2020). Sequence comparison of the
nsp12 from the Seattle, Washington isolate used in this study
versus SARS-CoV-2 isolates used in the previously mentioned
studies assessing RDV potency did not reveal consensus
changes in the nsp12 sequence, suggesting that any isolate-
specific variation in RDV sensitivity is not likely to be due to dif-
ferences in the RDV-TP interaction with the RdRp. Therefore,
the differences in EC50 values might be partially explained by
intrinsic differences in SARS-CoV-2 virus isolates, quantification
methods, Vero cell lineages, and assay conditions, such as incu-
bation period and virus input.6 Cell Reports 32, 107940, July 21, 2020Although Vero E6 cells support robust replication of SARS-
CoV-2, as illustrated here and elsewhere, our study emphasized
that caution should be exercised when interpreting nucleoside
prodrug potency experiments performed using Vero cell line-
ages. Nucleoside analog potency is dependent on metabolism
into the active form. In contrast to the nucleoside GS-441524,
RDV is a monophosphoramidate prodrug with moieties that
mask the negative charges of its monophosphate group, which
enhances its cellular uptake. Intracellularly, RDV is then rapidly
metabolized to its monophosphate, which is efficiently con-
verted to the active TP (Mehellou et al., 2018). Consistent with
previous reports for SARS-CoV and MERS-CoV (Agostini et al.,
2018), RDV showed a similar potency of inhibition against
SARS-CoV-2 over GS-441524 in Calu3 2B4 cells. In contrast,
RDV was 2-fold less potent than GS-441524 in Vero E6 cells.
The relative potency of the two compounds was directly linked
to intracellular concentration of the active TP metabolite, sug-
gesting an altered uptake and/or intracellular metabolism of
RDV, consistent with a previous report describing inefficient
metabolism of the nucleotide prodrug sofosbuvir in Vero cells
(Mumtaz et al., 2017). Drug potency in Vero E6 was similar
whether quantified by infectious virus or genome copy number.
In Calu3 2B4 cells, the potency determined by qRT-PCR was
about 2-fold lower than when quantified by plaque assay. It is
possible that qRT-PCR, which was developed to detect nucleo-
capsid (N) RNA, also detects packaged subgenomic RNAs and
defective genomes in addition to full-length genomes, resultingFigure 4. RDV-TP Levels in Vero E6, Calu3,
and HAE Cultures
Vero E6 cells, Calu3 2B4 cells, and HAE cultures
were incubated with RDV or GS-441524. At 8, 24,
and 48 h of treatment, whole-cell extracts were
prepared, and RDV-TP levels were quantified by
liquid chromatography-tandem mass spectrometry
(LC-MS/MS) as described in STAR Methods. RDV-
TP levels in Vero E6 and Calu3 2B4 cells represent
mean ± SD from n = 2 or 4 independent experi-
ments, respectively, each performed with duplicate
samples. RDV-TP levels in HAEs represent the
mean ± SD of four replicates for each individual







Figure 5. RDV Is Active against the SARS-CoV-2 RdRp In Vivo
The activity of RDV against the SARS-CoV-2 RdRp was evaluated using a chimeric SARS-CoV encoding the SARS-CoV-2 RdRp (SARS/SARS2-RdRp).
(A) Schematic of the recombinant SARS-CoVmouse-adapted MA15 strain chimeric virus genomes generated for these studies. SARS/SARS2-RdRp and SARS/
SARS2-RdRp-nanoluciferase (nLUC) were constructed by exchanging the SARS-CoV MA15 RdRp with the SARS-CoV-2 RdRp. ORF7 is replaced by nLUC in
SARS2-RdRp-nLUC.
(B) The presence of the SARS-CoV-2 RdRp was confirmed by Sanger sequencing in stocks of both recombinant chimeric viruses. Alignment of a stretch of
nucleotides from the SARS-CoV and SARS-CoV-2 RdRp highlighting nucleotides that differ between the two strains is shown in boldface. These SARS-CoV-2
RdRp-specific nucleotides are present in both chimeric viruses used in this study, as determined by Sanger sequencing and shown in the histogram.
(C) SARS/SARS2-RdRp-nLUC replication in Huh7 cells in the presence of RDV (left) and associated percent inhibition (right).
(D) SARS-CoV replication in Huh7 cells in the presence of RDV (left) and associated percent inhibition (right).
(E) Percent starting weight of 17-week-old female Ces1c/mice infected intranasally with 13 103 PFU of SARS/SARS2-RdRp and treated subcutaneously with
25 mg/kg RDV or vehicle 1 day post-infection (dpi) and twice daily thereafter.
(F) Lung hemorrhage at 5 dpi.
(G) Pulmonary function by WBP. The PenH metric shown is a surrogate marker of pulmonary obstruction. p < 0.0001 as determined by two-way ANOVA with
Sidak’s multiple comparisons test.
(H) Lung titer at 5 dpi as measured by plaque assay. p = 0.0012 by Mann-Whitney test.
In (E) and (G), boxes encompass the 25th–75th percentile, a line is drawn at the median, and whiskers represent the range.
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OPEN ACCESSin underestimation of the reduction in infectious titer. Notably,
the potency of RDV against SARS-CoV encoding the SARS-
CoV-2 RdRp in Huh7 cells was more than 100-fold higher than
that of RDV against bona fide SARS-CoV-2 in Huh7 and Calu3
2B4 cells. This difference could be due to infectivity, which is
driven by the SARS-CoV instead of the SARS-CoV-2 spike pro-
tein. In addition, SARS-CoV infects Huh7 cells at low frequency
at the MOI used in this study and does not appear to spreadthroughout the culture over the course of the experiment. The
number of Huh7 cells in which the virus replicates is relatively
lower compared with Calu3 2B4 cells, possibly enhancing the
overall antiviral effect of RDV in Huh7 compared with Calu3
2B4 cells. Interestingly, the antiviral potency of RDV against
SARS-CoV-2 in HAE cultures was comparable with SARS-CoV
and MERS-CoV (Sheahan et al., 2017), which is consistent with
the high conservation of the RdRp active site across theseCell Reports 32, 107940, July 21, 2020 7
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OPEN ACCESSdifferent CoVs. Together, these results emphasize the need for
careful selection and use of cell types and methods to study
the potency and efficacy of nucleoside analogs.
The target of RDV antiviral activity is the viral RdRp. To mirror
the pharmacokinetic exposures observed in humans, RDV
studies in mice must be performed in Ces1c/ animals (Shea-
han et al., 2017). In addition, SARS-CoV-2 does not readily infect
wild-type mice because of incompatibilities between the virus
spike and the murine ACE2 ortholog, which serves as the
SARS-CoV-2 entry receptor (Wan et al., 2020). Breeding of a
double-transgenic (hACE2, Ces1c/) mouse for use in RDV ef-
ficacy studies is ongoing. To rapidly assess the therapeutic effi-
cacy of RDV against SARS-CoV-2, we constructed SARS/
SARS2-RdRp. Virus entry, tropism, and pathogenesis of this
chimeric virus are driven by the parental mouse-adapted
SARS-CoV virus. Similar to our previous studies with SARS-
CoV (Sheahan et al., 2017), we now show that therapeutic
administration of RDV 1 dpi can reduce the viral load and
improve pulmonary function in mice. The kinetics of SARS-CoV
replication and disease are notably compressed in mice
compared with humans, where the virus titer peaks 10–
15 days after onset of symptoms (Hung et al., 2004; Peiris
et al., 2004). In comparison, initial reports suggest that SARS-
CoV-2 replication peaks around 5–6 days after symptom onset,
just prior to onset of dyspnea (Pan et al., 2020; Zhou et al.,
2020a). Importantly, a recent preprint described the therapeutic
efficacy of RDV against SARS-CoV-2 in rhesus macaques,
where RDV treatment reduced respiratory pathology and viral
loads in bronchoalveolar lavage fluid, consistent with our study
with a chimeric virus in mice (Williamson et al., 2020). Prior to
the emergence of pandemic SARS-CoV-2, RDV was evaluated
in phase 1 clinical trials as well as phase 2 randomized controlled
trials to treat acute Ebola virus disease in the Democratic Repub-
lic of Congo (DRC), and human safety data are available (Mu-
langu et al., 2019). Thus, our preclinical development of RDV
supported immediate compassionate use of RDV for severely
ill COVID-19 patients with promising early results (Grein et al.,
2020). Furthermore, a preliminary report of a large-scale, dou-
ble-blind, randomized, placebo-controlled trial in hospitalized
adults suggests that RDV shortened the time to recovery (Beigel
et al., 2020). This and other ongoing phase III randomized
controlled trials for treatment of patients with COVID-19 will ulti-
mately determine efficacy, safety, and optimal dosing of RDV in
patients with different stages of COVID-19.
Despite worldwide drug discovery efforts and over 300 active
clinical evaluations of potential treatments, no effective counter-
measure currently exists to combat COVID-19 (Sanders et al.,
2020) or likely future CoV pandemics. Large-scale deployment
of antiviral monotherapies creates a high risk for emergence of
drug resistance. Our previous work demonstrates that CoV resis-
tance to RDV is generated slowly and conferred by two mutations
in the RdRp. In addition, RDV-resistant CoVs exhibit reduced
replication capacity and are also more sensitive to another
potently active nucleoside analog inhibitor, b-D-N4-hydroxycyti-
dine (NHC; EIDD-1931/2801) (Agostini et al., 2019; Sheahan
et al., 2020b). Therapies combining direct-acting antivirals
(DAAs), such as RDV and EIDD-2801, along with other DAAs,
such as antibodies and protease inhibitors that target different8 Cell Reports 32, 107940, July 21, 2020stages of the viral replication cycle, could be considered for coun-
teracting resistance if it emerges in patients treated with antiviral
monotherapy. In addition, attention should be given to combining
DAAs with anti-inflammatory drugs to potentially extend the treat-
mentwindowduringwhichDAAs can improve outcomes.With zo-
onotic relatives of SARS-CoV, SARS-CoV-2, and MERS-CoV
continuing to circulate in bat species, more outbreaks of novel
CoVs are expected (Menachery et al., 2015b, 2016). Identification
and evaluation of broadly efficacious, robust anti-CoV therapies
are thus urgently needed at present and in the future.
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Andrea
Pruijssers (ardina.pruijssers@vumc.org).
Materials Availability
Plasmids generated in this study are available upon request.
Data and Code Availability
The pdb file containing SARS-CoV-2model showing RDV-TP in the active site has been deposited toMendeley Data: https://doi.org/
10.17632/x3sw5z2bg9.1.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cells, viruses, and compounds
Vero (ATCC CCL-81) and Vero E6 (ATCC CRL-1586) cells were purchased from ATCC and cultured in DMEM supplemented with
10% fetal bovine serum (FBS) (GIBCO, ThermoFisher Scientific) or 10% FCS fetal clonal serum (FCS)(HyClone, GE Life Sciences),
100 U/ml penicillin and streptomycin (GIBCO, ThermoFisher Scientific), and 0.25 mM amphotericin B (Corning). Human hepatoma
(Huh7) cells were provided by Dr. Mark Heise at UNC Chapel Hill and grown in DMEM supplemented with 10% FBS (Hyclone)
and 1 3 antibiotic-antimycotic (GIBCO, ThermoFisher Scientific). Calu3 2B4 cells (Yoshikawa et al., 2010) were cultured in DMEM
supplemented with 20% FBS, 100 U/mL penicillin and streptomycin, and 0.25 mM amphotericin B.
Primary HAE cell cultures used in antiviral activity assays were obtained from the Tissue Procurement and Cell Culture Core Lab-
oratory in the Marsico Lung Institute/Cystic Fibrosis Research Center at UNC. All assays in this report were performed using a single
HAE cell donor. Human tracheobronchial epithelial cells provided by Dr. Scott Randell were obtained from airway specimens re-
sected from patients undergoing surgery under University of North Carolina Institutional Review Board-approved protocols (#03-
1396) by the Cystic Fibrosis Center Tissue Culture Core. Primary cells were expanded to generate passage 1 cells and passage 2
cells were plated at a density of 250,000 cells per well on Transwell-COL (12mm diameter) supports (Corning). Human airway epithe-
lium cultures (HAE) were generated by provision of an air-liquid interface for 6 to 8 weeks to form well-differentiated, polarized cul-
tures that resembled in vivo pseudostratified mucociliary epithelium (Fulcher et al., 2005).
Clinical specimens of SARS-CoV-2 from a case-patient who acquired COVID-19 during travel to China and diagnosed in Wash-
ington State, USA upon return were collected as described (Holshue et al., 2020). Virus isolation from this patient’s specimens was
performed as described in Harcourt et al. (2020). The sequence is available through GenBank (accession number MN985325.1). A
passage 3 stock of the SARS-CoV-2 Seattle isolate was obtained from the CDC and passed twice in Vero E6 cells to generate high-
titer passage 5 stock for experiments described in this manuscript.
SARS-CoV expressing GFP (GFP replaces ORF7) was created from molecular cDNA clones as described (Scobey et al., 2013;
Sims et al., 2005). To create SARS-CoV expressing nanoluciferase (nLUC), the gene for GFP was replaced with nLUC and isolated
using our existing mouse adapted SARS-CoV (MA15) SARS-CoV Urbani molecular clone (Yount et al., 2003). A synthetic cDNA en-
coding the SARS-CoV-2 RdRp (Integrated DNA Technologies) was cloned into SARSMA15D fragment using StuI (50) and BsaI (30) via
Gibson assembly. The resultant plasmids were sequence confirmed and then utilized to generate recombinant virus with or without
nanoluciferase as described. Recombinant virus stocks were confirmed to harbor SARS-CoV-2 RdRp by Sanger sequencing.e2 Cell Reports 32, 107940, July 21, 2020
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A model of the elongating SARS-CoV-2 polymerase complex was generated based on a homology model which used the cryo-EM
structure of apo SARS-CoV as a template (PDB: 6NUR; Kirchdoerfer andWard, 2019) as described previously (Gordon et al., 2020b).
RNA primer and template, a substrate ATP and two catalytic Mg2+ ions were oriented in the structure based on alignment to a ternary
X-ray structure of HCV NS5B (PDB: 4WTD; Appleby et al., 2015). The structure was then optimized with a series of constrained min-
imizations. To this structure we aligned the new cryo-EM structure of the SARS-CoV-2 replication complex. As the SARS-CoV-2
structure does not significantly differ from the SARS-CoV structure, rather than a complete replacement of the model, we incorpo-
rated only those residues that had not been resolved in the previous structure (residues 31-116). Additional optimization, particularly
of the RNA in the exit channel, was done following the previously outlined procedures. After optimization of the ATP structure, RDV-
TP was modeled into the active site and minimized. Models of the V557L and F480L mutants and the other coronavirus models re-
ported here were generated based on this final model. All work was carried out using Prime andMacromodel (Schrödinger, LLC, New
York, NY, 2020). 3D coordinates of the SARS-CoV-2/RDV-TP model are provided in the Supplementary Material.
Sequence alignments
Coronavirus nsp12 sequence alignment was generated using CLC Workbench (QIAGEN) from sequences downloaded from the
NCBI website (Accession numbers MN985325.1 andMT123290.1) and from GISAID’s EpiFlu Database (Elbe and Buckland-Merrett,
2017; Shu and McCauley, 2017): Accession ID EPI_ISL_402124; virus name hCoV-19/Wuhan/WIV04/2019; Location: Asia / China /
Hubei / Wuhan; Collection date 2019-12-30 Originating lab Wuhan Jinyintan Hospital; Submitting lab Wuhan Institute of Virology,
Chinese Academy of Sciences; Authors Peng Zhou, Xing-Lou Yang, Ding-Yu Zhang, Lei Zhang, Yan Zhu, Hao-Rui Si, Zhengli Shi.
Accession ID EPI_ISL_412028; virus name hCoV-19/Hong Kong/VM20001061/2020; Location Asia / Hong Kong; Collection date
2020-01-22; Originating lab Hong Kong Department of Health; Submitting lab: School of Public Health, The University of Hong
Kong; Authors Dominic N.C. Tsang, Daniel K.W. Chu, Leo L.M. Poon, Malik Peiris.
Replication in different cell types
Vero E6, Vero, Calu3 2B4, and Huh7 cells were seeded in 24 well plates and allowed to adhere for 24 h. Cells were adsorbed with
100 ml SARS-CoV-2 in gel saline for 30 minutes (min) at 37C with manual rocking every 10 min. Virus inoculum was removed, cells
were washed in PBS, and 0.5 mL medium was added to each well. Supernatant was collected at 0, 24, 48, and 72 h post-infection,
and infectious viral titer in supernatants was determined by plaque assay.
Antiviral activity assays
Vero E6 cells were seeded at 13 105 cells per well, and Calu3 2B4 cells were seeded at 23 105 cells per well in 24-well plates (Corn-
ing). Cells were allowed to adhere for 16-24 h. Drugs were dissolved in DSMO and serially diluted in DMSO to achieve 1000x final
concentration. Equal volumes of each 1000x concentration were further diluted 1000-fold in medium up to 2 h before start of the
infection. Cells were adsorbed at MOI = 0.01 PFU/cell with SARS-CoV-2 in gel saline for 30min at 37C. Plates were rockedmanually
to redistribute the inoculum every 10 minutes. Viral inoculum was removed, and cells were washed with pre-warmed PBS+/+ (Corn-
ing) for 5 minutes. PBS+/+ was removed, and medium containing dilutions of RDV, GS-441524, or vehicle (DMSO) was added. Cells
were incubated at 37C. At 48 (Vero E6) or 72 (Calu3 2B4) hpi, supernatants were harvested and processed for plaque assay and RT-
qPCR.
Huh7 cells were plated at a density of 83 104 cells per well. Twenty-four hours later, fresh medium was added. Triplicate wells of
cells were infected for 1 h at 37C with SARS1/SARS2-RdRp-nLUC or SARS-CoV-nLUC diluted 1:100 in culture medium. Virus was
removed, cultures were rinsed once with medium, and fresh medium containing dilutions of RDV or vehicle (DMSO) was added.
DMSO (0.05%) was constant in all conditions. At 48 hpi, virus replication was measured by nLUC assay (Promega) using a Spectra-
Max plate reader (Molecular Devices).
Before infection, HAE cultures (approximately 1 3 106 cells per well) were washed with phosphate-buffered saline (PBS) and
moved into air-liquid interface medium containing various doses of RDV ranging from 0.00260 to10 mM (final DMSO, < 0.05%). Cul-
tures were infected with SARS-CoV-2 clinical isolate (2019-nCoV/USA-WA1/2020) at MOI = 0.5 PFU/cell for 2 h at 37C, after which
virus was removed and cultures were washed three times with PBS, followed by incubation at 37C for 48 h. The apical surface of
each culture was washed with PBS and collected for virus titration, measured as plaque-forming units (PFU) as previously described
for SARS-CoV (Scobey et al., 2013; Sims et al., 2005).
Cytotoxicity Assays
Cells were seeded at a density of 15,000 cells/well (Vero E6) or 30,000 cells/well (Calu3 2B4) in a white-wall clear-bottom 96-well plate
(Corning) and incubated at 37C overnight. Medium was removed, and serial dilutions of drug in medium were added to each wellCell Reports 32, 107940, July 21, 2020 e3
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facturer’s instructions at 48 h (Vero E6) or 72 h (Calu3). HAE cultures were treated with the same concentration range of drug in Trans-
well plates (Corning). Cytotoxicity in HAE was previously determined by RT-qPCR of TRIzol-extracted RNA (Sheahan et al., 2017)
Quantification of infectious viral titer
Approximately 13 106 Vero E6 cells/well were seeded in 6-well tissue culture plates (Corning) and allowed to grow to confluence for
48 h. Medium was removed, and 200 mL of 10-fold serial dilutions of virus-containing supernatants in gel saline were adsorbed in
duplicate for 30 min at 37C. Plates were rocked manually to redistribute inoculum every 10 minutes. Cells were overlaid with a
1:1 mixture of 2x DMEM and 2% agar in ddH2O and incubated at 37
C. Plaques were enumerated in unstained monolayers at
48-72 hpi using a light box.
Quantification of viral RNA copy number
Cell supernatants were harvested in TRIzol LS reagent (Invitrogen), and RNA was purified following phase separation by chloroform
as recommended by the manufacturer. RNA in the aqueous phase was collected and further purified using PureLink RNA Mini Kits
(Invitrogen) according to manufacturer’s protocol. Viral RNA was quantified by reverse-transcription quantitative PCR (RT-qPCR) on
a StepOnePlus Real-Time PCR System (Applied Biosystems) using TaqMan Fast Virus 1-Step Master Mix chemistry (Applied Bio-
systems). SARS-CoV-2 N gene RNA was amplified using forward (50-GACCCCAAAATCAGCGAAAT) and reverse (50-
TCTGGTTACTGCCAGTTGAATCTG) primers and probe (50- FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1) designed by the
United States Centers for Disease Control and Prevention (oligonucleotides produced by IDT, cat# 10006606). RNA copy numbers
were interpolated from a standard curve produced with serial 10-fold dilutions of N gene RNA. Briefly, SARS-CoV-2 N gene positive
control plasmid (IDT, cat# 10006625) served as template to PCR-amplify a 1280 bp product using forward (50-TAATACGACTCAC
TATAGGGATGTCTGATAATGGACCCCA) and reverse (50- TTAGGCCTGAGTTGAGTCAG) primers that appended a T7 RNA poly-
merase promoter to the 50 end of the complete NORF. PCR product was column purified (Promega) for subsequent in vitro transcrip-
tion of N RNA using mMESSAGEmMACHINE T7 Transcription Kit (ThermoFisher Scientific) according to manufacturer’s protocol. N
RNA was purified using RNeasy mini kit (QIAGEN) according to manufacturer’s protocol, and copy number was calculated using
SciencePrimer.com cop number calculator.
In vitro metabolism of RDV and GS-441524
Calu3 2B4 or Vero E6 cells were seeded in a 6-well plate at 8.03 105 or 3.5 X 105 cells/well, respectively. Twenty-four hours later, cell
culture media was replaced with media containing 1 mM RDV (GS-5734) or GS-441524 and incubated at 37C. Differentiated HAE
cultures from two healthy donors (MatTek Corporation; Ashland, MA) were maintained with media replacement every other day
for 1 week. The HAE donors were 56- and 62-year-old females of the same race. At the time of treatment, media was replaced
on the basal side of the transwell HAE culture, while the apical surface media was replaced with 200 mL media containing 1 mM
RDV. At 8, 24 and 48h post drug addition to all cultures, cells were washed 3 times with ice-cold tris-buffered saline, scraped into
0.5 mL ice-cold 70% methanol and stored at 80C. Extracts were centrifuged at 15,000 x g for 15 minutes and supernatants
were transferred to clean tubes for evaporation in a MiVac Duo concentrator (Genevac). Dried samples were reconstituted in mobile
phase A containing 3 mM ammonium formate (pH 5) with 10 mM dimethylhexylamine (DMH) in water for analysis by LC-MS/MS, us-
ing amulti-stage linear gradient from 10% to 50%acetonitrile inmobile phase A at a flow rate of 300 mL/min. Analytes were separated
using a 50 3 2 mm, 2.5 mm Luna C18(2) HST column (Phenomenex) connected to an LC-20ADXR (Shimadzu) ternary pump system
and HTS PAL autosampler (LEAP Technologies). Detection was performed on a Qtrap 6500+ (AB Sciex) mass spectrometer oper-
ating in positive ion and multiple reaction monitoring modes. Analytes were quantified using a 7-point standard curve ranging in con-
centration from 0.156 to 40 pmol prepared in extracts from untreated cells. For normalization by cell number, multiple untreated
Calu3 or Vero E6 culture wells were counted at each time point. HAE cells were counted at the 24-h time point and the counts for
other time points were determined by normalized to endogenous ATP levels for accuracy.
Formulations for in vivo studies
RDV was solubilized at 2.5 mg/mL in vehicle containing 12% sulfobutylether-b-cyclodextrin sodium salt in water (with HCl/NaOH) at
pH 5.0.
In vivo efficacy studies
All animal experiments were performed in accordance with the University of North Carolina at Chapel Hill Institutional Animal Care
and Use Committee policies and guidelines. To achieve a pharmacokinetic profile similar to that observed in humans, we performed
therapeutic efficacy studies in Ces1c/ mice (stock 014096, The Jackson Laboratory), which lack a serum esterase not present in
humans that dramatically reduces RDV half-life (Sheahan et al., 2017). 17 week-old femaleCes1c/mice were anaesthetized with a
mixture of ketamine/xylazine and intranasally infected with 103 PFU SARS1/SARS2-RdRp in 50 mL. One dpi, vehicle (n = 7) and RDV
(n = 7) dosing was initiated (25 mg/kg subcutaneously) and continued every 12 h until the end of the study at five dpi. To monitor
morbidity, mice were weighed daily. Pulmonary function testing was performed daily by whole body plethysmography (WBP)
(Data Sciences International) (Sheahan et al., 2017). At five dpi, animals were sacrificed by isoflurane overdose, lungs were scorede4 Cell Reports 32, 107940, July 21, 2020
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orrhage is a gross pathological phenotype readily observed by the naked eye and driven by the degree of virus replication, where lung
coloration changes from pink to dark red (Sheahan et al., 2017, 2020a). For the plaque assay, 53 105 Vero E6 cells/well were seeded
in 6-well plates. The following day, medium was removed, and monolayers were adsorbed at 37C for one h with serial dilutions of
sample ranging from 101 to 106. Cells were overlayed with 1X DMEM, 5% Fetal Clone 2 serum, 1 3 antibiotic-antimycotic, 0.8%
agarose. Viral plaques were enumerated three days later.
QUANTIFICATION AND STATISTICAL ANALYSIS
Mathematical and statistical analyses
The EC50 value was defined in GraphPad Prism 8 as the concentration at which there was a 50% decrease in viral replication relative
to vehicle alone (0% inhibition). Curves were fitted based on four parameter non-linear regression analysis. All statistical tests were
executed using GraphPad Prism 8. Statistical details of experiments are described in the figure legends.Cell Reports 32, 107940, July 21, 2020 e5
